Tositumomab and iodine I 131 tositumomab (the BEXXAR® therapeutic regimen) shows efficacy in elderly patients (pts) with relapsed/refractory low-grade (LG), follicular, and transformed non-Hodgkin's lymphoma (NHL).

被引：1

作者：

Gregory, SA

Zelenetz, A

Knox, SJ

Vose, J

Leonard, JP

Kaminski, M

机构：

[1] Rush Univ, Med Ctr, Chicago, IL 60612 USA

[2] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[3] Stanford Univ, Stanford Sch Med, Stanford, CA 94305 USA

[4] Univ Nebraska, Med Ctr, Omaha, NE USA

[5] Cornell Univ, Weill Med Coll, Ithaca, NY 14853 USA

[6] Univ Michigan, Ann Arbor, MI 48109 USA

来源：

BLOOD | 2004年 / 104卷 / 11期

关键词：

D O I：

10.1182/blood.V104.11.2630.2630

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2630

引用

页码：719A / 720A

页数：2

共 50 条

[1] Results of a randomized study of Bexxar™ (tositumomab and iodine I 131 tositumomab) vs. unlabeled tositumomab in patients with relapsed or refractory low-grade or transformed non-Hodgkin's lymphoma (NHL).
Davis, TA
Kaminski, MS
Leonard, JP
Gregory, SA
Wahl, R
Hsu, FJ
Wilkinson, M
Frankel, SR
Serafini, A
Zelenetz, AD
Kroll, S
Coleman, M
Levy, R
Knox, SJ
BLOOD, 2001, 98 (11) : 843A - 843A
[2] Tositumomab and iodine I 131 tositumomab (BEXXAR® therapeutic regimen) produces long-term durable responses in heavily pretreated patients with relapsed, refractory, and transformed low-grade non-hodgkin's lymphoma (NHL
Knox, SK
Meredith, RF
Coleman, M
Kaminski, MS
Zelenetz, AD
Vose, JM
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (01): : S220 - S220
[3] Tositumomab and iodine I 131 tositumomab: Efficacy and safety in 141 patients (pts) with previously untreated low-grade (LG) non-Hodgkin's lymphoma (NHL).
Kaminski, MS
Coleman, M
Link, BK
Wahl, RL
Goldsmith, SJ
Kostakoglu, L
Leonard, JP
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 575S - 575S
[4] The iodine I-131 tositumomab therapeutic regimen: Summary of safety in 995 patients with relapsed/refractory low grade (LG) and transformed LG non-Hodgkin's lymphoma (NHL)
Gregory, SA
Leonard, JP
Knox, SJ
Zelenetz, AD
Armitage, J
Kaminiski, M
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 615S - 615S
[5] Long-term results of a randomized trial comparing Tositumomab and Iodine-131 Tositumomab (BEXXAR®) with Tositumomab alone in patients with relapsed or refractory low-grade (LG) or transformed low grade (T-LG) Non-Hodgkin's Lymphoma (NHL).
Davis, T
Kaminski, MS
Leonard, JP
Hsu, FJ
Wilkinson, M
Wahl, R
Coleman, M
Goris, M
Levy, R
Knox, S
BLOOD, 2003, 102 (11) : 405A - 406A
[6] Efficacy and safety of Bexxar® (tositumomab and iodine I 131 tositumomab) in obese patients with low-grade non-Hodgkin's lymphoma.
Wahl, R
Goldsmith, SJ
Zasadny, KR
Alavi, A
Divgi, C
Hankins, J
JOURNAL OF NUCLEAR MEDICINE, 2003, 44 (05) : 415P - 415P
[7] Phase II study of CVP followed by tositumomab and iodine I 131 tositumomab (Bexxar therapeutic regimen) in patients with untreated follicular non-Hodgkin's lymphoma (NHL).
Link, B
Kaminiski, MS
Coleman, M
Leonard, JP
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 562S - 562S
[8] Re-treatment with Tositumomab and Iodine I131 Tositumomab (the BEXXAR® therapeutic regimen) in patients with non-Hodgkin's lymphoma (NHL) with a previous response to the BEXXAR therapeutic regimen.
Kaminski, MS
Knox, SJ
Radford, J
Gregory, SA
Leonard, JP
BLOOD, 2003, 102 (11) : 407A - 407A
[9] The effectiveness of tositumomab and iodine I 131 tositumomab in relapsed/refractory follicular grade 1/2 and small lymphocytic non-Hodgkin's lymphoma (NHL).
Armitage, JO
Leonard, JP
Gregory, SA
Horning, SJ
Zelenetz, AD
Kaminski, MS
Fisher, RI
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 575S - 575S
[10] Cost-effectiveness of tositumomab and iodine I-131 tositumomab (Bexxar therapeutic regimen (BTR)), in treatment of non-Hodgkin lymphoma (NHL)
Flowers, C. R.
Sambrook, J. C.
Briggs, A.
Osenenko, K.
Wang, H.
Dalal, M. R.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)

← 1 2 3 4 5 →